A Phase 1, Open-Label, Non-Randomized, Dose-Finding, Safety and Tolerability Study of Orally Administered Teysuno (S-1) in Combination With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
Disphar International B.V. is exploring the combination of Teysuno (S-1), a known oral chemotherapy agent, with epirubicin and oxaliplatin in patients with advanced solid tumors. The Phase 1 trial aims to establish the maximum tolerated dose (MTD) and assess safety and tolerability. Given the lack of established curative therapies for advanced solid tumors, this combination therapy could address a significant unmet medical need. The competitive landscape includes existing therapies for advanced solid tumors, but the unique oral formulation of S-1 may provide a differentiated offering. Diligence should focus on the safety profile and potential market acceptance of this combination therapy, especially in regions where oral chemotherapy is preferred.
Indication: Patients With Advanced or Metastatic Solid Tumors
Modality: combination therapy
Target: Oral administration of Teysuno (S-1) in combination with epirubicin and oxaliplatin targeting advanced solid tumors.
Sponsor: Disphar International B.V.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Oral administration of Teysuno (S-1) in combination with epirubicin and oxaliplatin targeting advanced solid tumors.
View original source fields
Condition raw: Patients With Advanced or Metastatic Solid Tumors
Condition normalized: Patients With Advanced or Metastatic Solid Tumors
Modality raw: combination therapy
Modality normalized: combination therapy
Target raw: Oral administration of Teysuno (S-1) in combination with epirubicin and oxaliplatin targeting advanced solid tumors.
Target normalized: Oral administration of Teysuno (S-1) in combination with epirubicin and oxaliplatin targeting advanced solid tumors.